Pharmacology and Experimental Therapeutics (PET)
The University of Bradford has a long standing reputation for excellence in Pharmacology and early stage drug discovery and development.
Much of the ground-breaking pharmacological characterisation of the anti-emetic blockbuster drug odansetron, one of the World Health Organisation’s List of Essential Medicines, was carried out by investigators in the School of Pharmacy and Medical Sciences at Bradford.
Bradford School of Pharmacy and Medical Sciences has been internationally recognised in Neuropharmacology, utilising preclinical behavioural models to develop novel agents for the treatment of a range of neurological disorders, and the underlying neurochemical processes responsible for disease.
Our primary aim is translational drug discovery for:
- neuroprotection (Alzheimer’s Disease, Motor Neurone Disease)
- cardiovascular disease (atherosclerosis, in-stent re-stenosis, vein graft failure, pulmonary arterial hypertension, diabetes-induced microvascular dysfunction)
The work includes target identification and identification of lead compounds.
Underpinning this aim are research programmes in the following areas:
- Molecular and cellular neuroscience in Alzheimer’s Disease and Motor Neurone Disease
- Molecular and cellular biology of chronic inflammation with a focus on cardiovascular diseases
- Therapeutic compound identification, isolation and synthesis, development of chemical biological tools and hit to lead development
Our emphasis is on sharing technologies (molecular and cellular biology, pre-clinical models of vascular dysfunction and neurodegeneration, high-content screening technologies) that underpin identification of disease processes at the molecular level, leading to the identification of new therapeutic targets and tool compounds. Our research is closely aligned with research activities in the Institute of Cancer Therapeutics and the Centre for Skin Sciences (CSS).